ClinicalTrials.gg
CompletedNCT07334223Updated Sep 16, 2026

Comparison of Intravenous Ondansetron and Low Dose Ketamine in Preventing Post Spinal Shivering

An interventional study of ondansetron and Ketamine (0.25 mg/kg) in Postoperative Shivering and Postspinal Shivering, sponsored by Mayo Hospital Lahore. Completed at 1 site in Pakistan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Mayo Hospital Lahore · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 6 months after the study started (first participant enrolled Jul 2020, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
All
01

Study summary

This randomized controlled trial assessed whether intravenous ondansetron is more effective than low dose ketamine in preventing shivering after spinal anesthesia in adults undergoing elective surgery. Post spinal shivering is a frequent and uncomfortable complication of spinal anesthesia and may increase oxygen demand and interfere with routine monitoring. Adults aged 20 to 70 years (body weight 50 to 80 kg; American Society of Anesthesiologists class I to II) scheduled for elective procedures under standardized spinal anesthesia were randomly allocated in equal numbers to receive either ondansetron 8 mg intravenously or ketamine 0.25 mg/kg intravenously, administered 5 minutes after the spinal injection. Perioperative temperature management was standardized for all participants. The primary outcome was the occurrence of post spinal shivering during intraoperative monitoring. Among 180 participants, shivering occurred in 30.0% of those receiving ondansetron and 44.4% of those receiving ketamine, showing a statistically significant reduction with ondansetron.

02

Conditions studied

  • Postoperative Shivering
  • Postspinal Shivering

Keywords

  • Spinal anesthesia
  • Postoperative shivering
  • Shivering prophylaxis
  • Ondansetron
  • Ketamine
03

In context

Lead sponsor

Mayo Hospital Lahore is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of either gender aged 20-60 years with ideal body
  • weight of 50 to 80 kg.
  • Patients meeting I and II determined by
  • anesthesiologist.
  • Patients undergoing elective surgeries under spinal anesthesia.
  • Duration of surgery should not be more than 3 hours.

Exclusion criteria

Exclusion Criteria:

  • Patients having a documented history of severe adverse reactions to ketamine or ondansetron.
  • Patients with cardiovascular disease documented in history.
  • Patients with hepatic disease documented in history and supported by lab results ( 32-40U/L), ALT(10-40U/L).
  • Patients with renal disease documented in history and supported by lab results. Urea (10-50mg/dl) S/Creatinine (0.3-1.5mg/dl).
  • Patients with hyperthyroidism documented in history and supported by lab results.
  • Patients with history of mental illness, seizures and glaucoma.
  • Patients with known hypertension (BP greater than 140/90).
  • Haemodynamically unstable patients (BP\<100mmHg).
  • Patients with coagulopathy or other bleeding diathesis documented in history and supported by lab results.
  • Complicated prolonged surgeries in spinal anesthesia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Group Ondansetron

    Received 8 mg of ondansetron administered intravenously five minutes after spinal anesthesia for prophylaxis of post spinal shivering.

    Drug: ondansetron

  • Active comparator
    Group Low Dose Ketamine

    Received ketamine 0.25 mg per kilogram administered intravenously five minutes after spinal anesthesia for prophylaxis of post spinal shivering.

    Drug: Ketamine (0.25 mg/kg)

Interventions

  • 8 mg ondansetron administered intravenously as a single dose five minutes after spinal anesthesia.

    Also known as: Serotonin type 3 receptor antagonist

  • DrugKetamine (0.25 mg/kg)

    Drug page: Ketamine

    0.25 mg per kilogram ketamine administered intravenously as a single dose five minutes after spinal anesthesia.

    Also known as: N-methyl-D-aspartate receptor antagonist

06

What researchers measure

Primary outcomes

  1. Frequency of Post Spinal Shivering

    Occurrence of post spinal shivering following administration of study medication, assessed clinically by the anesthesiology team and recorded as present or absent during intraoperative monitoring after spinal anesthesia.

    Time frame: From 5 minutes after administration of study drug until transfer of the patient to the post-anesthesia care unit

07

Study locations

1 site
  • Mayo Hospital, Lahore
    Lahore, Punjab Province 54000, Pakistan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jan 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2026
First posted
Jan 12, 2026
StartActual
Jul 1, 2020
Primary completionActual
Jan 30, 2021
CompletionActual
Jan 30, 2021
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07334223
Lead sponsor
Mayo Hospital Lahore
Responsible party
Adeel Ahmed (Principal Investigator, Mayo Hospital Lahore) — Principal investigator
First posted
Jan 12, 2026
Start date
Jul 1, 2020
Primary completion
Jan 30, 2021
Completion
Jan 30, 2021
Last update
Sep 16, 2026

Study contacts

Adeel Ahmed
principal investigator · Mayo Hospital Lahore

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ondansetron

Start the discussion